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DISSERTATION ABSTRACT 
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Epstein-Barr Virus (EBV) is a ubiquitous human B-lymphotrobic herpesvirus that latently 
infects over 90 percent of the world's population. EBV infection is usually benign in healthy 
people. However, EBV is the causative agent of infectious mononucleosis, and is strongly 
associated with an increasing number of human malignancies, including Burkitt's lymphoma, 
nasopharyngeal carcinoma, Hodgkin's disease, and immunoblastic lymphomas in 
immunocomprised people. EBV has the ability to immortalize B cells in vitro and stimulate 
B-cell proliferation. Mutagenesis of the viral genome has defined a subset of five genes 
required for transformation (EBNA1, -2, -3, -6 and LMP1). The LMP1 gene is of particular 
interest since it is an oncogene that is involved in the transformation as well as proliferation of 
B cells latently infected by EBV. The aim of this thesis is to investigate the molecular 
mechanisms of transcriptional regulation of the LMP1 gene in B cells. 
The LMP1 promoter is controlled by both positive and negative transcriptional cis-elements 
and the gene is inactive without inducers. EBNA2 can overcome the repression of the LMP1 
promoter. By deletion analyses, two distinct LMP1 regulatory sequence (LRS) regions, -106 
to +40 and -176 to -136, relative to the transcriptional initiation site, were shown to contribute 
to the EBNA2-responsiveness in LRS. In the distal EBNA2 responsive region, both the 
octamer motif (bound by a POU domain protein) and the PU box-binding site (bound by a 
PU.l factor) were critical for the EBNA2 induction process. Cooperation between the factors 
binding to these two sites is required for full EBNA2 transactivation, and EBNA2 may be 
targeted to the LMP1 promoter via interacting with the POU domain protein. 
In the promoter-proximal region (LRS-106/+40), mutational analyses showed that both an 
Sp site and an ATF/CRE site are important in the EBNA2-dependent activation of the LMP1 
promoter. Overexpression of Spl and ATF1/CREB1 mediates activation of the LMP1 
promoter independently of EBNA2 via their respective binding sites, whereas EBNA2-
induced activation occurs through a direct contact between EBNA2 and ATF-2/c-Jun 
heterodimer via the ATF/CRE site. 
We have also shown that a silencing element overlaps with a transcriptional enhancer 
element in an LRS sequence that contains an E-box-homologous motif. Transient co-
transfection analyses showed that USF proteins confer EBNA2-independent activity on the 
LMP1 promoter via the E-box site and that this activation was downregulated by the Max-
Madl-mSin3A factors. In addition to the E-box site, we have also identified an adjacent 
Ikaros site that binds Ikaros factors, which also functions as a repressive element. 
The repression exerted by the factors binding to the E-box site and the Ikaros site was 
released by an inhibitor of histone deacetylation, Trichostatin A (TSA), indicating that histone 
deacetylation plays an important role in repression mediated by these factors. EBNA2 
relieved Hie repression through an indispensable response element in the -107/-95 LRS region, 
which contains a functional AP-2 site. AP-2 factors cooperated with EBNA2 to overcome the 
repression exerted by the E-box and the Ikaros site binding factors, which led to the activation 
of the LMP1 promoter in reporter plasmids. 
Key words: Epstein-Barr virus, B-cell, transformation, LMP1, LRS, EBNA2, transcription, 
transactivation, repression, histone deacytylation 
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ABSTRACT 
Epstein-Barr Virus (EBV) is a ubiquitous human B-lymphotrobic herpesvirus that latently 
infects over 90 percent of the world's population. EBV infection is usually benign in healthy 
people. However, EBV is the causative agent of infectious mononucleosis, and is strongly 
associated with an increasing number of human malignancies, including Burkitt's lymphoma, 
nasopharyngeal carcinoma, Hodgkin's disease, and immunoblastic lymphomas in 
immunocomprised people. EBV has the ability to immortalize B cells in vitro and stimulate 
B-cell proliferation. Mutagenesis of the viral genome has defined a subset of five genes 
required for transformation (EBNA1, -2, -3, -6 and LMP1). The LMP1 gene is of particular 
interest since it is an oncogene that is involved in the transformation as well as proliferation of 
B cells latently infected by EBV. The aim of this thesis is to investigate the molecular 
mechanisms of transcriptional regulation of the LMP1 gene in B cells. 
The LMP1 promoter is controlled by both positive and negative transcriptional cis-elements 
and the gene is inactive without inducers. EBNA2 can overcome the repression of the LMP1 
promoter. By deletion analyses, two distinct LMP1 regulatory sequence (LRS) regions, -106 
to +40 and -176 to -136, relative to the transcriptional initiation site, were shown to contribute 
to the EBNA2-responsiveness in LRS. In the distal EBNA2 responsive region, both the 
octamer motif (bound by a POU domain protein) and the PU box-binding site (bound by a 
PU.l factor) were critical for the EBNA2 induction process. Cooperation between the factors 
binding to these two sites is required for full EBNA2 transactivation, and EBNA2 may be 
targeted to the LMP1 promoter via interacting with the POU domain protein. 
In the promoter-proximal region (LRS-106/+40), mutational analyses showed that both an Sp 
site and an ATF/CRE site are important in the EBNA2-dependent activation of the LMP1 
promoter. Overexpression of Spl and ATF1/CREB1 mediates activation of the LMP1 
promoter independently of EBNA2 via their respective binding sites, whereas EBNA2-
induced activation occurs through a direct contact between EBNA2 and ATF-2/c-Jun 
heterodimer via the ATF/CRE site. 
We have also shown that a silencing element overlaps with a transcriptional enhancer element 
in an LRS sequence that contains an E-box-homologous motif. Transient co-transfection 
analyses showed that USF proteins confer EBNA2-independent activity on the LMP1 
promoter via the Ebox site and that this activation was downregulated by the Max-Madl-
mSin3A factors. In addition to the E-box site, we have also identified an adjacent Ikaros site 
that binds Ikaros factors, which also functions as a repressive element. 
The repression exerted by the factors binding to the E-box site and the Ikaros site was 
released by an inhibitor of histone deacetylation, Trichostatin A (TSA), indicating that histone 
deacetylation plays an important role in repression mediated by these factors. EBNA2 
relieved the repression through an indispensable response element in the -107/-95 LRS region, 
which contains a functional AP-2 site. AP-2 factors cooperated with EBNA2 to overcome the 
repression exerted by the E-box and the Ikaros site binding factors, which led to the activation 
of the LMP1 promoter in reporter plasmids. 
Key words: Epstein-Barr virus, B-cell, transformation, LMP1, LRS, EBNA2, transcription, 
transactivation, repression, histone deacytylation 
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LCV Lymphocryptovirus 
LMP Latent membrane protein 
LRS LMP-1 gene regulatory sequence 
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MAPK Mitogen-activated protein kinase 
MHC Major histocompatibility complex 
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Spl Stimulatory protein 1 
STAT Signal transducer and activator of transcription 
TAF TBP-associated factor 
TBP TATA box-binding protein 
TNFR Tumor necrosis factor receptor 
TPA Tetradecanoyl phorbol acetate 
TRAF Tumor necrosis factor receptor-associated factor 
TRADD Tumor necrosis factor receptor-associated death domain protein 
TSA Trichostatin A 
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INTRODUCTION 
The Epstein-Barr Virus (EBV) is a ubiquitous human herpes virus, infecting over 90 percent 
of the world's population and persisting for the lifetime in B cells in a latent infection. The 
virus is usually benign in healthy people. Primary infection usually takes place in the first few 
years of life and does not result in any recognized disease. However, the dramatic immune 
response that can occur when primary infection is delayed until adolescence or adulthood, 
frequently results in infectious mononucleosis. EBV is also associated with several human 
malignancies derived from B cells, T cells, NK cells, epithelial cells and perhaps other tissues 
as well, including endemic Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC), 
Hodgkin's disease, gastric carcinomas, certain rare T-cell lymphomas, and immunoblastic 
lymphomas in immunocomprised people [1]. 
EBV is remarkable for the efficiency with which it can cause proliferation of the B cells that it 
infects. In vitro, EBV has the ability to establish a latent infection in proliferating B 
lymphoblasts. However, EBV does not establish latency in a proliferating lymphoblast in 
vivo, but in a resting memory B cell. EBV encodes genes that can cause cell growth and 
prevent cell death and these are thought to play a role in the establishment of viral persistence 
because the virus transits in B cells through lymph nodes into the memory B-cell 
compartment. Only a few of the 85 genes encoded by the virus are necessary for the 
transforming ability of EBV. The latent membrane protein 1 (LMP1) gene is one of the genes 
involved in the deregulation of cell growth and is known to be a viral oncogene. The 
expression of LMP1 is regulated both by general signal transduction pathways and by the 
EBV-encoded proteins. Detailed knowledge of the transcriptional regulation of the LMP1 
promoter will improve the understanding at the molecular level of the roles played by the 
virus in the pathogenesis of virus-associated lymphomas. 
1. Regulation of gene expression 
The regulation of gene expression is central to cell differentiation and development. Gene 
expression can be controlled at six different levels: transcription or RNA synthesis, RNA 
processing, mRNA transport, mRNA stability, translation or protein synthesis, and protein 
stability. Eukaryotic genes appear to be regulated primarily at the level of transcription. 
Transcription is the process where the information stored within genes is copied into 
messenger RNAs (mRNAs). Once the primary transcript or pre-mRNA has been formed, a 
series of processing events occur that lead to the production of the mature transcript: the 
primary transcript is generally capped at its 5' end by a 7-methylguanylate (cap structure) and 
polyadenylated at its 3' end (poly A tail). The primary transcript is spliced to remove introns 
interrupting the exons. The splicing of pre-mRNA is not a stable process, and alternative 
splicing can lead to a variety of transcripts encoding distinct protein products, thus increasing 
the coding capacity of genes. Alternative splicing is often tightly regulated in a cell-type or 
developmental-stage-specific manner, and it is an important regulatory step in gene 
expression. Capped/polyadenylated transcripts are generally more stable and associate more 
easily with ribosomes, ensuring a higher rate of translation. The process of producing the 
mature transcript is believed to be linked to transport through the nuclear membrane. 
In the cytoplasm, the mature RNA transcript becomes associated with ribosomes and a 
polypeptide chain is produced according to the information coded by RNA, a process known 
as translation. The stability of RNA, i.e. how long RNA remains translatable in the 
cytoplasm, is also another step at which expression levels can be controlled. The protein itself 
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can also be subjected to post-translational modification, which may influence targeting of the 
protein for degradation. In this thesis, I will focus on the regulation of gene expression by 
transcriptional mechanisms. 
2. Eukaryotic transcription 
Regulation of transcription is a fundamental process in biology. Central to tie transcription 
process is the necessity for an RNA polymerase (Pol) to reach the promoter and transcribe the 
ensuing DNA sequence into the complementary RNA molecule. RNA polymerases are 
enzymes that catalyze the formation of 3'-5' phosphodiester binding between ribonucleoside 
triphosphates. In eukaryotes, there are three different RNA polymerases, RNA polymerases I-
III. Each RNA polymerase seems to transcribe a specific class of genes: Ribosomal RNA 
(rRNA) genes are transcribed by Pol I, transfer RNA (tRNA) genes, the 5 S Ribosomal RNA 
genes and the U6 small nuclear RNA genes are transcribed by Pol III, whereas protein coding 
genes and most small nuclear RNA genes are transcribed by Pol II, mostly giving rise to 
mRNA. 
2.1 Promoter Structure 
Genes are DNA sequences coding for proteins or RNA. Generally, DNA sequences upstream 
of a gene contain regulatory regions, including regulatory eis elements that can be recognized 
by trans factors (transcriptional activators or repressors), which positively or negatively affect 
the level of transcription. The regulatory elements are highly variable and gene-specific, 
located in a promoter-proximal position or many kilobases away in a promoter-distal position. 
For a typical gene, the core promoter is defined as the sequence immediately adjacent to and 
upstream of the gene that specifies the start and direction of transcription. The core promoter 
consists of an initiation site (Inr), the TATA box (TATA), downstream promoter element 
(DPE) and the upstream regulatory regions (Fig. 1). There are two kinds of promoters: TATA 
containing promoters and TATA lacking promoters. A typical promoter usually contains a 
TATA box (a sequence rich in the nucleotides A and T) at around 30 base pairs upstream of 
the transcriptional start site. The LMP1 promoter is also a TATA containing promoter. 
2.2 Basal transcription machinery 
Eukaryotic RNA polymerases cannot function alone and they require an enormous array of 
co-factors, termed general transcription factors (GTFs), to achieve transcription. The ability of 
pol II to initiate transcription from a given point and at a defined frequency is dependent upon 
interactions of DNA-binding proteins with the core promoter and the regulatory region. Every 
core promoter requires the GTFs, which include TFIID, TFIIA, TFIIB, TFIIF, TFIIE, and 
TFIIH [2], 
Mechanistic studies using purified eukaryotic systems have divided the process of RNA pol II 
transcription into distinct steps or stages. Among these steps are promoter recognition, 
formation of a preinitiation complex, initiation, promoter clearance, elongation, termination, 
and reinitiation [3]. In vitro, the GTFs and Pol II can be assembled onto a promoter in an 
ordered stepwise pathway [3], The first basal factor to bind the core promoter is TFIID, a 
large multi-subunit complex composed of TBP and several tightly bound associated factors 
TAFs. TBP sits as a saddle on the TATA element and causes a major bend in the DNA. This 
brings sequences both upstream and downstream of the TATA box into a closer proximity to 
each other [4], After the binding of TFIID at the TATA box, TFIIA, TFIIB, TFIIF-pol II, 
TFIIE and finally TFIIH bind in a stepwise assembly, forming a pre-initiation complex (PIC). 
Although the GTFs and Pol II can be assembled at the promoter in an ordered stepwise 
pathway, considerable evidence has accumulated that transcriptional initiation may normally 
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involve core promoter binding by a pre-assembled holoenzyme complex containing Pol II and 
many or all of GTFs that are essential for initiation [5]. 
The assembly of the initiation complex is followed by PIC activation, where the double-
stranded DNA forms a "bubble" near the PIC (promoter opening/melting) and transcription is 
then initiated. The transcription initiation is defined by the formation of the first 
phosphodiester bond, whereas the promoter clearance is the point where the polymerase 
leaves the initiation complex to start transcript elongation. After initiation, escape into 
elongation is concomitant with phosphoiylation of the C-terminal domain (CTD) of pol II. 
The elongation phase continues until the transcribing polymerase terminates transcription, 
usually 0.5-2 kb past the termination/polyadenylation signal sequence. The various phases of 
transcription are associated with alternative GTFs. Some components of the PIC remain 
associated with the elongation complex (TFIIF), whereas other factors (TBP or TFIID) remain 
at the promoter after promoter clearance or are sequentially dissociated (TFIIB, TFIIE, 
TFIIH). At or after the termination stage, dephosphorylation of the CTD by a CTD-specific 
phosphatase returns the polymerase to a stage capable of PIC assembly. 
2.3 Transcription factors 
The expression levels of genes transcribed by Pol II are predominantly controlled by a 
complex system of the specific transcription factors that interact with each other and with the 
eis DNA regulatory elements located distal of the core promoter. Most of these transcription 
factors are DNA-binding proteins composed of two functional domains: a specific DNA-
binding domain and a regulatory domain. The activities of the domains can be independently 
regulated by a number of mechanisms: oligomerization; action of inhibitory molecules; ligand 
binding; protein-protein interactions; and post-translational modifications such as 
phosphorylation or dephosphorylation. These changes can alter the DNA-binding 
characteristics, the activation ability, or the sub-cellular localization of a transcription factor. 
The transcription factors are classified according to the features of their protein structure, 
which account either for their interaction to DNA or for their formation of multimers, often 
dimers. Transcription activators can also be grouped according to the protein composition in 
their activation domains. Transcription activators function through interacting with 
components of the PIC directly or via co-regulators. 
2.4 Chromatin modification and transcription regulation 
The active state of a gene is determined not only by transcription factors but also proteins that 
modify the structure of chromatin. The purpose of the chromatin remodeling proteins is to 
alter the nucleosome architecture such that genes become exposed to or hidden from the 
transcriptional machinery. Genomic DNA is packed into fundamental units known as 
nucleosomes. A nucleosome contains approximately 146 base pairs of DNA wrapped around 
an octamer of histone proteins (consisting of two copies of each histone protein H2A, H2B, 
H3 and H4). All genomic DNA is further packed together in highly ordered structures (termed 
chromatin) with the help of histone protein HI. The chromatin is an environment in which 
transcription initiates inefficiently, because the histone proteins are too strongly associated 
with DNA and prevent transcription factors and the transcription machinery from gaining 
access to promoters. Therefore, an alteration of chromatin structure is often necessary and a 
first step for transcriptional initiation. Two highly conserved mechanisms for altering 
chromosome structure have been identified: 1. the movement of nucleosomes along DNA, 
which is carried out by ATP-dependent chromatin remodeling complexes such as the Swi/Snf 
complex and NuRD complex; and 2. the post-translational modification of core histones 
including methylation, phosphorylation and acetylation. Histone acetylation is probably the 
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best understood of these covalent modifications where hyper-acetylation by histone acetyl 
transferases (HATs) leads to increased transcription of particular genes and hypo-acetylation 
of histones by histone deacetylases (HDACs) has an opposite effect. Many studies have 
identified several large, multisubunit enzyme complexes responsible for the targeted 
acetylation/deacetylation of histones, as well as ATP-dependent chromatin remodeling 
complexes (reviewed in [6, 7]). 
isieao/Dpy 
iodific:ifi»ii 
Chromatin 
remodelin" 
iT^TÄHL&DPE;" 
Figure 1. The regulatory network of transcription is assembled by multisubunit complexes, including the 
transcription machinery, co-regulatory complexes, and transcription factors. The first step for transcription 
regulation is to alter the nucleosomal architecture where gene activation or repression demands structural 
changes at the chromatin level. Chromatin modifying activities can be targeted to promoters to alter chromatin 
structure and thereby modulate the accessibility for interacting proteins. Activation of transcription is controlled 
by coactivator complexes that mediate activation of transcription by activators located in a promoter-proximal 
position (PA) or many kilobases away in a promoter-distal position (DA). Also, the composition and sequence of 
the core promoter directs the formation of the pre-initiation complex (PIC) and defines the start site of 
transcription. This involves the interplay of basal transcription factors and RNA polymerase with distinct core 
promoter elements such as TATA box (TATA), Initiator ( Inr), and downstream promoter element (DPE) to 
position the pre-initiation complex. Modified from [8], 
3. The Epstein-Barr Virus 
The Epstein-Barr Virus (EBV), a B-lymphotropic human herpesvirus, is one of the most 
common viruses that infect humans. Over 90 percent of humans carry this yl-herpesvirus for 
lifetime (reviewed in [9] ). Two different EBV types are found in the human population: type 
1 and type 2 (type A and B). Only a few of the genes differ between these two virus types. In 
vitro studies suggest that the type 1 virus is more efficient in transforming B cells than the 
type 2 virus. 
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3.1 EBV Replication 
The EBV genome, which is encased within a nucleocapsid surrounded by the viral envelope 
in the virion, consists of a linear 172-kb DNA molecule (reviewed in [9]). The DNA is 
segmented by internal repeats (IR) and unique (U) regions, which have been characterized by 
BamHl restriction endonuclease fragments (from A-Z), depending on fragment size. After 
infecting the cells, the linear EBV genome becomes circular at its cohesive terminal repeats 
(TR), forming an episome. The virus exists predominantly in this circular form in infected 
cells. EBV is sometimes integrated into the host genome at some, but not any specific 
integration site. The virus replicates once during each cell cycle using the replication 
machinery of the host. The DNA synthesis starts in a region called oriP, the origin of plasmid 
replication. It is composed of the family of repeats (FR) and the dyad symmetry (DS) regions 
[10, 11]. The DS sequence contains the initiation site for replication whereas the FR part is 
required for the replication process and also functions as a transcriptional enhancer. Induction 
of lytic replication is spontaneously activated in only a small percentage of latently infected B 
cells from orilyt, the origin of lytic replication [12]. 
3.2 EBV Infection 
EBV infects a variety of cell types, mainly the mucosal epithelial cells and B cells. The 
infection of epithelial cells is a primarily lytic infection with production of virus, whereas the 
B-cell infection is a predominantly latent infection. EBV can also infect T lymphocytes and 
even smooth muscle cells since the virus is found in some T-cell ly mphomas and smooth-
muscle tumors in transplant recipients (reviewed in [13]). 
The EBV life cycle starts when the virus primarily infects epithelial cells in the oropharynx 
(Figure 2). Infection of B-lymphocytes with EBV occurs in the oropharyngeal lymphoid 
organs. Active viral replication takes place in mucosal lymphoid tissue in the oropharynx, and 
released virus is transmitted via the saliva. Before the virus enters the B cell, the major 
envelope glycoprotein, gp350/220, binds to the viral receptor, the CD21 molecule (the C3d 
complement receptor) [14], on the surface of the B cell. Other factors in addition to CD21 are 
important for infection. The major-histocompatibility-complex (MHC) class II molecule 
serves as a cofactor for infection of B cells [15]. Cross-linking of surface molecule by the 
viral glycoproteins provides the necessary signals to trigger the resting B cells to leave the 
resting state (GO) and enter the Gl state in the cell cycle [16]. During this time, the earliest 
expressed latent proteins EBNA2 and EBNA5 (or EBNA leader protein, LP) are induced from 
the Wp promoter that is present in multiple copies in the viral genome. EBNA2 and EBNA5 
drive the cells through the first Gl and the transcriptional activator EBNA2 activates 
promoters necessary to produce the full range of latent proteins. At this point EBNA 
transcription switches from Wp to Cp [17], a promoter that works optimally in B 
lymphoblasts. The latent proteins block terminal differentiation and drive the B cells to 
proliferate. The proliferation of EBV-infected B cells in primary infection is accompanied by 
the development of a vigorous cytotoxic T-lymphocyte (CTL) response directed against both 
latent and lytic viral proteins (reviewed in [1]). The EBV-infected B cells can differentiate 
through a germinal center reaction as centroblasts and centrocytes that express EBNA1 and 
LMPs, but not EBNA2 whose functions are believed to drive cell proliferation and to block 
cell differentiation. These cells exit into the peripheral circulation as resting memory B cells 
that are transcriptionally quiescent for viral latent genes and, thus, not recognized by the 
immune system [18]. Only a small percentage of the circulating B cells are infected by the 
virus, ranging from 2 to 60 cells per million [19]. 
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The role of the lymphoblastoid form of latency is proposed to provide EBV with access to the 
memory B cell compartment where the virus can persist for the life time of the infected host 
without being cleared by the immune response (reviewed in [20]). During persistence, latently 
infected memory B-cells transit through mucosal lymphoid tissue where they may become 
activated. A few of these activated cells exit the cell cycle to replenish the pool of infected 
memory cells, but most cells migrate into the mucosal epithelium, terminally differentiate and 
release infectious virus. 
EBV 
• • • 
/3ZZ35 ItZZ SU/SS #. # • • 
LMP2 
CD2 Lytic phase 
Resting B-cell 
CTL 
Transformation 
LMPl, -2 LMP2 LMPl 
CTL 
Lymphoblast Centroblasts/centrocytes Memory B-cell 
• Latency III Latency II j Latency 0 
Lymph node Peripheral circulation 
Figure 2. The Epstein-Barr virus life cycle. A detailed description is given in the text. Modified from [18]. 
3.3 EBV Latency Programs 
EBV has been suggested to exist in three different kinds of latency programs (reviewed in 
[1]). These are all distinct from the lytic cycle. Under the primary infection, EBV will infect 
resting B cells, and drive them into a latently infected, proliferating lymphoblastoid state. This 
lymphoblastoid form of latency is referred to as latency III, which is also characteristic of 
EBV-positive Burkitt's lymphoma (BL) cell lines with what is termed a group III phenotype. 
This step is considered to be a transient phase in vivo, but in vitro, these EBV-infected B cells 
will be immortalized into permanently growing lymphoblastoid cell lines (LCLs). In LCL 
cells, a limited set of latent gene is expressed, which compromises two small nuclear RNA 
molecules (EBV-encoded RNAs, EBER1 and 2), six EBV nuclear antigens (EBNA1-6), three 
membrane proteins (latent membrane proteins LMPl, 2A, 2B) and various spliced BamHl A 
rightward transcripts. Of these EBV-latent genes, only five (EBNA1, EBNA2, EBNA3, 
EBNA6, and LMPl) are absolutely essential, whereas EBNA5 is important, for B-cell 
transformation by EBV. 
14 
A much more restricted pattern of latency (latency I), characterized by the expression of 
EBNA1 (from Qp promoter), EBERs and the BamHl A rightward transcripts, is seen in 
Burkitt's lymphoma biopsies. While an intermediate program (latency II) with expression of 
the LMPs as well as the EBERs, the BamHl A rightward transcripts and EBNA1, is found in 
germinal center (GC) B cells [18], as well as in EBV-associated malignancies such as 
Hodgkin's disease, nasopharyngeal carcinoma (NPC), and T/NK-cell lymphomas. 
Recently, a form of latent infection was described for infected memory B cells in the 
peripheral circulation of healthy carriers. This form of infection is referred to as the latency 0 
or the true latency program [20], In this case no viral latent genes are expressed [21], with the 
possible exception of LMP2A expression whereas EBNA1 expression can be detected 
sporadically [22-24]. 
3.4 EBV and diseases 
EBV was originally discovered in a cell line derived from a Burkitt's lymphoma by Epstein 
and Barr in 1964. Since then, EBV has been linked to the pathogenesis of an increasing 
number of both benign and malignant diseases (reviewed in [1, 13]). The potential of EBV to 
drive indefinite cell proliferation, in combination with environmental and genetic factors, 
increases the risk of cellular genetic alterations and consequently malignancy. 
Infectious Mononucleosis (IM) 
Infectious Mononucleosis is caused by delayed EBV infection of adolescents and adults and is 
a benign lymphoproliferative disorder. IM is characterized by a proliferation of EBV-infected 
cells in lymphoid tissues such as tonsils. In IM, the full range of viral proteins characterized 
of latency III is expressed. However, analysis at the single cell level has revealed a degree of 
heterogeneity with cells expressing latency I, II, and III patterns being detectable [25]. After 
several weeks the infection ceases due to a vigorous cytotoxic T-lymphocyte (CTL) response. 
Burkitt's lymphoma (BL) 
BL was the first human tumor to be linked to a viral infection, and EBV was first discovered 
in BL cells. BL cells contain a chromosome translocation of the c-myc gene (chromosome 8) 
into one of the immunoglobulin loci (chromosome 14, -2, or -22), leading to abnormal 
regulation of c-myc expression. Expression of the c-myc in EBV-immortalized B cells results 
in increased tumorigenicity of the cells. EBV has been demonstrated in virtually all cases of 
endemic BL; whereas only up to 30% of sporadic cases occurring in Western Europe or in 
North America are EBV associated. In EBV-positive BL cases, the virus is present in all 
tumor cells and the viral genomes have been shown to be of monoclonal origin. The 
expression of EBV-latent genes is limited to the EBERs and EBNA1. Thus, those latent viral 
proteins that are recognized by EBV-specific CTLs are not present in BL, allowing BL cells 
to escape EBV-specific immunity. 
Hodgkin 's disease (HD) 
HD is characterized by the presence of a small number of malignant mononuclear Hodgkin 
and multinuclear Reed-Sternberg cells. EBV has been detected in the Hodgkin and Reed-
Sternberg cells of up to 40% of HD cases in western countries and the viral genomes are 
monoclonal. EBV-gene expression in HD is restricted to the EBERs, EBNA1, LMP1, 
LMP2A and LMP2B, consistent with a type II latency. 
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Nasopharyngeal carcinoma (NPC) 
NPC occurs with a high incidence in certain parts of Southeast Asia, Northern Africa, and 
among Alaskan Eskimos, but sporadically in Western Europe and North America. Nearly 
100% poorly/undifferentiated NPCs contain EBV genomes and express EBV proteins as type 
II latency. The EBV episome is present as a monoclonal episome. The expression of LMP1 in 
NPCs is consistent with the ability of the protein to inhibit terminal differentiation of the 
epithelial cells. In addition to EBV infection, other factors (such as environmental risk factors 
and genetic susceptibility) also play a role in the development of NPC. 
EBVlymphoproliferative diseases (or Immunoblastic lymphomas) 
These can be observed in patients with severe immunodeficiencies, such as AIDS, X-linked 
lymphoproliferative disease and drug-induced immunosuppression in transplant recipients. 
These patients have impaired T-cell immunity and are unable to control the increased virus-
driven lymphoproliferations of EBV-infected B cells. EBV lymphoproliferative disease can 
be either monoclonal, oligoclonal, or polyclonal and usually shows a type III latency. 
Oral Hairy Leukoplakia 
Oral Hairy Leukoplakia occurs in HIV-infected patients as well as in some immuno-
suppressed transplant recipients. It is a nonmalignant hyperplastic lesion of epithelial cells. 
The lesions show active viral replication and expression of lytic viral proteins, but EBNA1 is 
also detected. 
EBV DNA or proteins have been detected in several other cancers, including T/NK-cell 
lymphoma, peripheral T-cell lymphomas, lymphoblastoid granulomatosis, central nervous 
system lymphomas in non-immunocompromised patients, smooth-muscle tumors in 
transplant recipients, and gastric carcinomas (reviewed see [13]). 
3.5 EBV-encoded latent proteins 
EBV encode a large variety of proteins that enable the virus to survive despite a vigorous 
immune response. Each of these proteins performs a specific function, and they are expressed 
in the host cell at different phases according to the need of the virus. 
EBNA1 
EBNA1 is essential for the replication and maintenance of the EBV episome [26] by binding 
as dimers to binding sites within EBV origin of plasmid replication, oriP. This binding also 
activates a transcriptional enhancer activity in oriP which can activate expression of Cp-
initiated viral genes, and the LMP1 gene over a distance of 10 kb [27]. EBNA1 is expressed 
in all EBV-infected cell lines from different promoters. The amino terminal half of EBNA1 
contains a 239-amino acid region of repeating glycine-glycine-alanine residues which 
inhibits proteasomal degradation and presentation to CTLs [28], EBNA1 is required for B-cell 
immortalization and might be oncogenic, since mice carrying an EBNA1 transgene driven by 
the immunoglobulin heavy chain promoter/enhancer developed B cell lymphomas at a high 
frequency [29]. 
EBNA2 
EBNA2 is essential for initiation and maintenance of EBV driven B-cell immortalization [30, 
31]. EBNA2 in the absence of other EBV proteins can be oncogenic, as 90% of transgenic 
mice expressing EBNA2 from the SV40 early enhancer-promoter developed kidney tumors 
[32]. EBNA2 contributes to transformation by acting as a transcriptional coactivator. EBNA2 
regulates expression of cellular genes, such as the B-cell activation markers CD21 and CD23, 
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as well as the proto-oncogene c-myc [33]. In addition, EBNA2 activates genes encoding EBV 
nuclear and membrane proteins through regulating the Cp and LMP promoters (reviewed in 
[9]). EBNA2 cannot bind to DNA directly but interacts with cellular DNA-binding proteins, 
including RBP-JK (also called CBF-1) and PU.l [34-39], and some other transcription factors 
presented in this thesis. EBNA2 may contribute to transcriptional activation by recruiting 
TFIIB, TFIIE, TFIIH, RPA70, and TAF40 basal transcription machinery to the promoter [40-
42], EBNA2 may also facilitate transactivation by interaction with hSNF5/Inij| components 
of the SNF-SWI complex, to alter the nucleosome structure of target genes [43]. EBNA2 can 
also interact with the histone acetytransferases (HATs) CBP, P300 and PCAF in activation of 
LMP1 promoter [44]. EBNA2 is able to activate promoters through interaction with RBP-JK 
protein, which is also the target of the Notch signaling pathway. EBNA2 is consider to be a 
biological equivalent of an activated Notch receptor (reviewed in [45]). By molecular genetic 
analyses, the RBP-JK binding domain and the acidic domain of EBNA2 were both required 
for B-cell immortalization [46, 47]. 
EBNA5 (also known as EBNA LP) 
EBNA5 and EBNA2 are the first viral proteins expressed during EBV infection of B cells. 
EBNA5 is not required for EBV immortalization of B cells, but its presence enhances 
transformation [31]. EBNA5 cooperates with EBNA2 to activate transcription of the LMP1 
gene [48, 49] and the cyclin D2 gene [16]. Recently, EBNA5 was shown to repress gene 
expression by inhibition of the polyadenylation process with the result that reporter RNA is 
not exported to the cytoplasm for translation [50], 
EBNA3, -4, -6 (also referred as EBNA-3A, -3B, -3C respectively) 
EBNA3, -4, -6 are encoded by three genes that are adjacent within the EBV genome, with a 
high degree of sequence similarity. Only EBNA4 is dispensable for B-cell immortalization, 
whereas EBNA3 and -6 are essential. EBNA6 can transform rat embryo fibroblasts and 
functions as an oncoprotein [51]. All three proteins can bind to RBP-JK, preventing RBP-JK 
from binding to DNA, and inhibits EBNA2-mediated transactivation of the LMP2A promoter 
[52]. All three proteins have been shown to participate in transcriptional regulation of the 
LMP1 gene as well as several cellular genes (reviewed in [9]). EBNA6 was reported to 
interact with a histone deacetylase (HDAC1), indicating that the repression of transcription 
could be mediated through histone deacetylation [53]. EBNA6, but not EBNA3 or -4, was 
also found to activate transcription from the LMP1 promoter in conjunction with EBNA2 
[54]. Like EBNA2, EBNA6 binds directly to PU.l in vitro [54], 
LMP1 
LMP1 is an oncoprotein that is essential for B-cell immortalization. A detailed description of 
the LMP1 function is given in a later section. 
LMP2A and -2B 
LMP2A and -2B are integral membrane proteins. LMP2A interferes with signal transduction 
through interaction of its hydrophilic Nterminal domain with Lyn and Fyn tyrosine kinases 
[55, 56], LMP2A blocks signal transduction from surface immunoglobulins. By blocking the 
switch from latency to lytic cycle, LMP2A may prevent reactivation of the latent virus. In 
addition to blocking B cell antigen receptor (BCR) signaling, LMP2A can substitute for a 
BCR-mediated survival signal in B cells lacking membrane immunoglobulin, as expression of 
LMP2A in transgenic mice allows non-transformed B cells to survive even in the absence of 
normal BCR signaling [57]. 
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Table 1. EBV-encoded latent proteins and their possible functions 
EBV-encoded 
latent proteins 
Function Required for 
transformation 
Latency 
EBNA1 Essential for viral replication and maintenance of the EBV 
episome, transactivates the LMP 1 promoter and Cp via 
interaction with OriP 
+ 0*, I-III 
EBNA2 Viral oncogene, transactivates cellular and other latent 
viral genes, functional homologue of Notch 
+ III 
EBNA5 (-LP) Cooperates with EBNA2 in transactivation, implicated in 
transcriptional repression by inhibition of the 
polyadenylation process 
+/-* HI 
EBNA3 (-3A) Transcriptional regulator + III 
EBNA4 (-3B) Transcriptional regulator 
-
III 
EBNA6 (-3C) Viral oncogene, transcriptional regulator III 
LMPI Viral oncogene, induces B-cell activation and adhesion, 
protects cell from apoptosis 
+ ii-m 
LMP2A Prevents EBV reactivation and lytic cycle, blocks and/or 
substitutes BCR signals 
-
o, ii-m 
LMP2B Modulates LMP2A function 
-
o, ii-m 
* EBNA1 expression can be detected sporadically 
* Not essential but enhances efficiency of B-cell transformation 
3.6 Latent Membrane Protein 1 
LMP1 is often expressed in EBV-associated cancers, suggesting a role in the initiation or 
maintenance of transformation. It has been shown in vitro that LMP1 is necessary for EBV to 
immortalize primary B cells [58] and for the resulting LCLs to continue proliferating [59]. 
The expression of LMP1 transforms rodent fibroblasts [60] and human keratinocyte cell line 
[61] and induces a phenotype characteristic of B-cell activation in primary B cells [62]. 
Evidence that LMP1 has the ability to transform cells in vivo was provided in a study of 
transgenic mice expressing LMP1 under the control of the Ig heavy chain promoter [63], 
These mice developed B-cell lymphomas, directly demonstrate the oncogenic potential of 
LMP1. 
Structure and Location of Latent Membrane Protein 1 
The LMP1 protein is encoded by the BamHl N leftward reading frame 1 (BNLF1) in EBV 
genome. The structure of LMP1 predicted from the ORF in the cDNA was a 386-residue 
integral membrane protein with six transmembrane segments (Figure 3). A short 23-residue 
amino terminus and a long 200-residue carboxyl terminus were both predicted to be located 
on the cytoplasmic side of the membrane (reviewed in [9]). The LMP1 protein sizes range 
between 57 and 67 kDa due to a variable number of repeats in the LMP1 gene. Other 
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variations are also found in LMP1 genes from NPC biopsy samples from specific 
geographical areas and include a point mutation within an Xhol restriction site and a 30 bp 
deletion [64], The loss of Xhol site has no obvious link to LMP1 function, whereas the 
deletion of 30 bp in the C terminal part of LMP1 correlates with stronger transforming ability 
of the protein. 
LMP1 is concentrated in glycosphingolipid-rich membrane regions, which also mark the 
clustering sites for G protein-associated receptors. LMP1 clustering is not ligand dependent 
and no external ligand has been identified that interacts with the three short loops exposed on 
the surface of immortalized cells. Mutational analyses demonstrate that the amino terminus 
and the trans-membrane segments of LMP1 mediate the aggregation of LMP1 into patches, 
whereas clustering of LMP1 in the membrane of infected cells is an essential feature of the 
immortalizing phenotype of EBV. 
Signaling by Latent Membrane Protein 1 
The molecular basis for the EBV oncoprotein LMP1 in transformation is its ability to 
constitutively activate the tumor necrosis factor receptor (TNFR) signal transduction pathway 
[65]. Aggregation, mediated by the transmembrane domains, causes LMP1 to behave as a 
constitutively activated receptor [66], It is the C-terminal of LMP1 that performs the signaling 
function, the N-terminal domain is only required for its tethering to the cytoskeleton. Whereas 
LMP1 is capable of transforming immortal rodent cell lines [60], overexpression of LMP1 in 
B cells results in cytotoxicity [67]. LMP1 acts as a constitutively active TNFR (reviewed in 
[68]). LMP1 has several effects similar to those seen in the activation of CD40, a member of 
the TNFR family; even the C-terminal domain of LMP1 and the cytoplasmic domain of CD40 
are functionally interchangeable [59]. The C-terminal domain of LMP1 contains a consensus 
Tumor Necrosis Factor Receptor-associated Factors (TRAFs) binding motif and has been 
shown to associate with several members of the TRAF family, in particular TRAF1 and 
TRAF3, and with the Tumor Necrosis Factor Receptor-associated death domain protein 
(TRADD) (reviewed in [68]). These protein-protein interaction regions are required for both 
immortalizing activities and signal transduction of LMP1. 
One of the principal effects of LMP1 clustering with TRAFs and TRADD is the activation of 
NFKB regulated genes [69]. The interactions of TRAFs and TRADD with LMP1 are mediated 
by separate regions within the C-terminal domain termed Transformation Effector Sites (TES) 
or C Terminal Activation Regions (CTAR) [69, 70] (Figure 3). CTAR1 activates NFKB to a 
low degree, whereas CTAR2 activates 70-80% of the NFKB activity. Signaling to NFKB from 
both CTAR1 and CTAR2 requires NFKB-inducing kinase (NIK), IKB-regulatory kinases 
(IKKa and IKKß) [71]. In recent years, it has become apparent that LMP1 initiates other 
signaling pathways in addition to NFKB. CTAR2 activates c-Jun N-terminal kinase (JNK) in a 
TRADD- and TRAF2-dependent manner (reviewed in [68]). The LMP1 signaling pathway to 
JNK and NFKB apparently does not overlap downstream of TRAF2, and there is no cross talk 
between these two pathways since inhibition of one does not affect the other. LMP1 has also 
been reported to activate several ether MAPK family members: the extra-cellular response 
kinase (ERK) 1, -2 and p38. LMP1, via an intermediate domain between CTAR1 and 
CTAR2, can also interact with the Janus kinase 3 (JAK3), which in turn activates JAK/STAT 
pathway. This domain is not required for transformation. 
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Figure 3. Schematic representation of the signaling pathways engaged by LMP 1. LMP 1 is an integral membrane 
with six transmembrane domains, which confers aggregation and oligomerization at the cell membrane. Three C-
terminal domains are identified, CTARl, CTAR2 and CTAR3. CTARl binds TRAF1-3, and -5, and activates 
the NFKB a nd p38 pathways. CTAR2 binds TRAF2 and TRADD and stimulates the NFKB, p38 and INK 
pathways. Both CTARl and -2 domains can activate STATs pathways, although an intermediate domain binds 
of JAK3 and activates JAK/STATs pathways independently of CTAR1/CTAR2. All these signals lead to 
transcriptional regulation of various cellular genes. Modified from ([68]). 
Protection from apoptosis by Latent Membrane Protein 1 
One interesting feature of LMP1 is that whereas ectopic overexpression may be cytostatic, the 
LMP1-expressing cells are protected from apoptosis [72-75]. Several studies have shown that 
LMP1 expression protects cells from p53-mediated apoptosis. Upregulation of Bcl-2, Mcl-1 
and A20 anti-apoptotic genes appears to be the principal underlying mechanism [72, 75, 76], 
Transgenic mice expressing LMP1 develop B-cell lymphomas and the tumor cells show 
increased levels of bcl-2 and A20, suggesting that these genes may have an important role in 
lymphomagenesis [63]. 
3.7 The regulation of the LMP1 gene expression in B cells 
The expression of LMP1 in EBV-transformed B lymphocytes is tightly regulated by both 
EBV-encoded proteins and cellular factors that are part of general signal transduction 
pathways through promoter elements targeted by ubiquitous as well as B-cell-specific 
proteins. Previous investigations have suggested that the LMP1 gene regulatory sequence 
(LRS) is composed of both positive and negative transcriptional eis elements, and the gene is 
inactive in the absence of inducers [77-79]. As mentioned above, all the EBNAs are 
implicated in the regulation of LMP1 gene expression. Among them, EBNA2 is a most potent 
transactivator of LMP1 gene expression in B cells. Although the regulation of the LMP1 
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promoter has been extensively investigated, the mechanism by which EBNA2 overcomes the 
repression of the promoter is still not fully understood. 
Promoter usage 
There are several different promoters identified in different cell lines to express the LMP1 
gene. In B cells, the EcoRI D leftward promoter 1 (ED-LI) is the primarily utilized promoter. 
This promoter was shown to be a latent promoter active in the B cell line B95-8, giving rise to 
a 2.8-kb long transcript [80]. This thesis focuses on the regulation of this promoter. Another 
promoter designated ED-L1A was identified and shown to be active in the late lytic phase in 
B cells resulting in the expression of a truncated LMP1 protein [81]. Cloning of the LMP1 
gene from an NPC biopsy from a Chinese identified ED-LI, ED-L1A, and ED-LIB [82]. 
Another study in a nude mouse-passaged NPC cell line CI5 showed that two 3' coterminal 
LMP1 mRNAs of 2.8 and 3.5 kb have been detected at equal levels [83]. The 3.5 kb transcript 
initiates from heterogeneous start sites within the first terminal repeat (TR) of the viral 
genome. The presence of different promoters will ensure the virus to express the LMP1 gene 
under different conditions. Furthermore, some EBV strains differ with respect to the LMP1 
coding exons and the LMP1 regulatory sequence present in the genes. This indicates that the 
expression of these different LMP1 genes will vary depending on the cellular context and 
virus type present in a cell. 
Regulation of LMP1 gene expression by DNA methylation 
It has been shown that sequence-specific methylation is involved in the regulation of the 
LMP1 promoter [84]. Methylation of the EBV genome varies in different cell lines. The 
LMP1 promoter is nearly unmethylated in LCLs and partially methylated in Daudi cells, but 
Mly methylated in latency I Rael cells [85, 86]. Treatment of BL type I cell line Rael with 5-
azacytidine, a cytosine demethylation agent, can induce EBNA2-6 and LMP1 expression [87]. 
Regulation of LMP1 gene expression by PKA and PKC signal pathways 
Previous studies have shown that cAMP increases LMP1 expression in the EBV-positive cell 
lines Cherry and B95-8 via protein kinase A (PKA) pathway [88], Treatment of BL cell lines 
with anti-immunoglobulin, n-butyrate or with tetradecanoyl phorbol acetate (TPA) also 
induces the LMP1 expression in EBV-positive cell lines independent of EBNA2 via the 
protein kinase C (PKC) signal transduction pathway [89, 90]. These studies indicate that the 
expression of LMP1 gene can be activated by inducers other than EBNA2. 
Regulation of LMP1 gene expression by other EBNAs 
As previously mentioned, all the EBNAs are implicated in the regulation of LMP1 gene 
expression. EBNA1 can activate expression of the LMP1 gene over a distance of 10 kb 
through binding to oriP [27]. Moreover, EBNA2-mediated activation of the LMP1 promoter 
can be potentiated by EBNA5 [48, 49]. EBNA3, -4, -6 are suggested to repress gene 
expression of EBNA2-responsive promoters by preventing RBP-JK from binding to DNA [52, 
91]. EBNA6, but not EBNA3 or -4, was also found to activate transcription from the LMP1 
promoter in conjunction with EBNA2 through interacting with PU.l transcription factor via 
PU-box element [54], 
The LMP1 gene regulatory sequence (LRS) 
Extensive studies on the LMP1 gene regulatory sequence (LRS) have been done to 
characterize the mechanisms involved in regulation of the LMP1 gene expression, and several 
regulatory elements have been identified [36, 77-79, 92] (Figure 4). A region between -54 to 
+40 relative to the ED-LI promoter initiation site contains a constitutively active regulatory 
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element [77, 78]. Two other positive cis-activating regulatory components (-155 to -147 and -
234 to -205) were also defined [79]. Subsequent studies have identified a cellular sequence-
specific DNA binding protein RBP-JK bind ing to an RBP-JK site between LRS position -223 
to -213 [36, 92, 93], and the Ets-related transcription factors PU.l (Spi-1) and Spi-B binding 
to one PU box element [36, 92]. Johannsen et al have also identified several LMP1 binding 
factors (LBF1-7), but their exact nature and functions are still unknown [92]. Later studies 
have focused on the RBP-JK site and its binding factor RBP-JK/CBF1, because EBNA2 
interacts with RBP-JK and stimulates transcription from promoters with this binding site [34-
39]. RBP-JK binding sites are present in all EBNA2-regulated promoters discovered so far. 
Thus, this gives rise to an attractive hypothesis that RBP-JK may target EBNA2 to EBNA2-
responsive elements in EBNA2-regulated promoters as an essential step in EBNA2-induced 
transactivation. However, this does not seem to be the case for the LMP1 gene, which retains 
EBNA2 responsiveness even when the RBP-JK sites are deleted [47, 77, 78, 92, 94]. This is 
also consistent with the observation that RBP-JK has a much lower affinity for its binding site 
in the LRS context than for the corresponding sites in the Cp or CD23 promoter [95]. All 
these results suggest that there must be other factors binding to downstream elements to 
confer EBNA2-responsiveness on the LMP 1 promoter. 
The results from our group have previously shown that the LMP1 promoter is controlled by a 
complex set of both positive and negative transcriptional c/.s-elements, and hat EBNA2 can 
overcome the repression effects, whereas LRS region -214 to +40 is sufficient to mediate this 
EBNA2-induction [77, 78], Another investigation from our group has identified the 
importance of an activating transcription factor/cyclic AMP response element (ATF/CRE) in 
the proximal part of LRS, and showed that the LMP1 promoter can be activated by c AMP 
through this ATF/CRE site in the absence of EBNA2 [88]. 
RBP-JK RBP-JK PU-box ATF/CRE 
ED-LI 
]• 
-634 
-300 -200 
LBF2, 3, 5, 6, 7 LBF4 
-100 -50 + 1 +40 
Figure 4. Schematic representation of the identified cw-elements in the LMP1 gene regulatory sequence (LRS) 
of B95-8 EBV DNA origin. The numbers indicate the nucleotide positions relative to the transcription initiation 
site (+1). A detailed description of the cw-elements is discussed in the text. 
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PRESENT INVESTIGATION 
1. Aim of the present study 
The expression of the Epstein-Barr vims latent membrane protein 1 (LMP1) is regulated by 
both EBV-encoded proteins and cellular specific factors. Previous investigations 
demonstrated that the LMP1 gene regulatory sequence (LRS) is composed of both positive 
and negative transcriptional eis elements, and that the gene is inactive in the absence of the 
inducers. The EBV nuclear antigen 2 (EBNA2) has been shown to transactivate a number of 
viral and cellular gene promoters including the LMP1 promoter. The overall aim of the 
present study is to increase our knowledge about the molecular mechanisms of EBNA2-
induced activation of expression of the LMP1 gene in B cells. 
2. Methodological Considerations 
Reporter Plasmids 
Reporter plasmids are commonly used as a tool to investigate the activity of promoters in 
gene expression. In these plasmids the promoter of interest or a fragment of the regulatory 
sequence is inserted in front of a gene encoding an enzyme or some other protein, the 
concentration of which is easily determined. Plasmids containing the chloramphenicol acetyl 
transferase (CAT) or the luciferase genes have been utilized in the present study of the LMP1 
gene promoter. The plasmids are introduced into the eukaryotic cells by transfection. The 
promoter region will control the expression of the reporter gene and the activity of the 
promoter will be reflected by the level of reporter protein in the cells or secreted by the cells. 
However, it is important to keep in mind that the amount of gene product measured at a 
certain time point is determined by the difference between the rate of synthesis and the rate of 
degradation both at the mRNA and the protein level. Thus, the protein level is not a direct 
measure of the rate of transcription initiation, which has to be measured with other methods 
like nuclear run on assays. There are, however, several advantages with the reporter plasmid 
system. Since it is easy to create mutations and deletions in the promoter region of interest, 
reporter gene assays allow a detailed examination of transcription regulatory regions. In 
addition, there is usually no shortcomings caused by interference by the reporter gene product 
which might occur with the endogenous system. Furthermore, the assay provides a 
quantitative measurement of the reporter protein with high sensitivity, and is easy to perform. 
However, since the level of the reporter protein does not differentiate correct promoter 
initiation usage of the transcript and may not fiilly mirror the frequency of transcription 
initiation during promoter activation, the validity of the method should be verified at the RNA 
level with methods such as primer extension, SI RNase mapping or RNase protection. 
Moreover, it is also important to consider that the protein usually is more stable than the 
mRNA. The CAT protein has a half-life of approximately 50 hours and will accumulate over 
time from transfection to harvest. In contrast, the luciferase reporter protein with a half-life of 
3 hours will give information on promoter activity around the time of harvest. It is also 
important to perform the appropriate kinetic control experiments to ensure that the 
measurements of enzyme activity are done in the linear range of the concentration curve. 
DNA-protein binding assay 
Eukaryotic genes appear to be regulated primarily at the level of transcription, as mentioned 
above. Regulation of transcription as a response to environmental signals is a fundamental 
process in biology. The ability of RNA polymerase II to initiate transcription from a given 
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nucleotide position in the gene (promoter) and at a defined frequency is dependent upon 
interactions of sequence specific DNA binding proteins with the core promoter and upstream 
elements in the regulatory regions. There are several different ways to study the DNA-protein 
interaction, such as electrophoretic mobility shift assay (also known as gel shift assay), DNase 
I footprinting analysis and methylation interference assay. In this study, EMSA was chosen to 
investigate DNA-protein interaction because it is a simple and sensitive method for many 
applications. This method separates DNA-protein complexes from free DNA by non-
denaturing Polyacrylamide gel electrophoresis (PAGE), on the basis of differences in charge, 
conformation and size. 
An EMSA experiment consists of several steps: preparation of the DNA probe; preparation of 
the protein extracts; preparation of the gel; gel electrophoresis and autoradiography. EMSAs 
are often used, as in the present study, to define the core DNA sequence in a regulatory 
element essential for binding a transcription factor, to identify the protein binding to a 
regulatory element by specific antibodies in a supershift assay and to study protein-protein 
interaction by the use of in vitro translated protein (or recombinant proteins or purified 
proteins) to the EMSA binding mixture. 
RNase protection assay 
To confirm that the observed transactivation of the reporter plamids was due to transcripts 
correctly initiated from the LMP1 promoter, the ribonuclease protection assay (RPA) was 
employed. RPA is a technique used for detection and quantification of specific RNAs, as well 
as for mapping of transcription initiation and termination sites and intron-exon boundaries. 
The basic approach of RPA is solution hybridization of an antisense-labeled RNA probe to 
cellular RNA, followed by treatment with ribonucleases. The enzymes specifically degrade 
single-stranded RNA while leaving the RNA-RNA hybrids intact. The size of the protected 
fragment is determined by Polyacrylamide gel electrophoresis and visualized by 
autoradiography. Compared to Northern blot (the standard method to analyze RNA 
transcripts) and SI mapping analysis, RPA is more sensitive because solution hybridization is 
more efficient than filter-based hybridization and can accommodate larger amounts of total or 
poly(A)-containing RNA samples. RPA is also more tolerant to partially degraded RNA and 
allows simultaneous detection of multiple mRNA targets. Cytoplasmic RNA was prepared 
and analyzed by the RNase protection assay (in Paper II) as described previously [96]. 
3. Results and Discussion 
Paper I 
PU box-binding transcription factors and a POU domain protein cooperate in the 
Epstein-Barr virus (EBV) nuclear antigen 2-induced transactivation of the EBV latent 
membrane protein 1 promoter. 
In this report, we confirm and extend our previous observation that the LMP1 promoter can 
be activated by EBNA2 in the absence of RBP-jK-binding sites in the LMP1 gene regulatory 
sequence (LRS) [77-79]. It demonstrates by transient transfection assays into the EBV-
negative B cell line DG75 that two distinct LRS regions, -106 to +40 and -176 to -136, 
contribute to the EBNA2-responsiveness. Site-directed mutation analysis of the distal EBNA2 
responsive region revealed that two discrete c «-acting elements were required for full 
promoter function. These same elements analyzed by electrophoretic mobility shift assay 
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(EMSA) defined two binding sites recognized by nuclear factors in B cells. An octamer like 
sequence (-147/-139) contained partially overlapping binding sites for an unidentified 
transcriptional repressor on the one hand and a factor belonging to the POU domain family 
but distinct from Oct-1 and Oct-2 on the other. An adjacent purine tract (-170/-156) held a 
PU.l binding site, which was also recognized by a related factor (Spi-B protein) [36]. Our 
further investigation of the probability of EBNA2 interacting with the transcription factors 
binding to these two sites, however, showed by EMSA that EBNA2 interacts with the POU 
domain protein. The results suggest that the POU domain protein can assist in the targeting of 
EBNA2 to the LMP1 promoter. The results of EMSA analysis indicated that the POU domain 
protein and either of the two PU box-binding proteins bind simultaneously to LRS, creating a 
ternary complex that might participate in the EBNA2 transactivation of the LMP1 promoter. 
There were no qualitative differences between EBV-negative and EBV-positive cells 
regarding transcription factor binding to the octamer motif or to the PU box binding site as 
revealed by EM S As. 
The sequence at position -147/-139 in LRS with a partial identity to the octamer motif 
suggested that a member of the Oct family of transcription factors might be responsible for 
the effect of this LRS element on LMP1 promoter activity. We have, however, not been able 
to demonstrated binding of Oct-1 and Oct-2 factors, which are expressed in B cells, to this site 
with specific antibodies. The Oct factors belong to a large family of transcription factors 
designated as POU domain proteins, characterized by a unique bipartite DNA-binding domain 
(the POU domain). The POU domain includes a variant homeodomain (POU-H) domain and 
a conserved POU-specific (POU-S) domain connected by a variable linker. Both subdomains 
contain helix-turn-helix motifs that directly associate with the two components of bipartite 
DNA-binding sites (ATGCAAAT) (review see [97]). Using an antibody against the POU-
specific domain we demonstrate that both EBV-positive and EBV-negative B-cells contain a 
distinct factor that binds to the octamer motif in the context of surrounding LRS sequences. If 
LRS sequences upstream of position -146 in the binding site were deleted, the POU domain 
protein was replaced by an unidentified factor, suggesting that the octamer motif-carrying 
sequence contain two overlapping protein-binding sites. Interestingly, the binding of the 
unidentified factor correlated with a complete loss of EBNA2-responsiveness. Deletion of 
further 2 bp resulted in loss of binding of the unidentified factor, which correlated to the 
restitution of EBNA2-responsiveness to almost the same level as when the POU domain 
protein was bound. It is, however, not immediately obvious what role this putative silencer 
might play in the regulation of the LMP1 promoter activity, since the binding of the POU 
domain protein to an unmutated octamer motif always dominated over that of the unidentified 
repressor in both EBV-positive and EBV-negative cells. Repeated attempts to isolate the 
putative silencer of the LMP1 promoter by purification were unsuccessful. 
What role do the octamer and PU box elements play in the induction of the LMP1 promoter 
by EBNA2? Evidence reported by several groups strongly suggests that the EBNA2 protein 
does not bind directly to a specific DNA motif but acts via protein-protein interaction with the 
regulatory region of affected promoters. There are several possible candidates for the 
targeting of EBNA2 to the LMP1 promoter, including RBP-JK (also called CBF-1) at the 
RBP-JK site [34-39], Ets-related PU.l factor at the PU box [36, 92], the POU domain protein 
at the octamer motif (this investigation), as well as several other transcription factors binding 
to sites in the promoter-proximal region (Paper II and IV in this thesis). The PU-box and PU.l 
could not convey EBNA2 responsiveness by themselves since a reporter plasmid containing 
only the PU.l-binding site but not the octamer motif (pLRS(-181/-145)TKCAT) was not 
induced by EBNA2. Furthermore, a series of reporter plasmids derived from pLRS(-106)(-
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181/-145)CAT, which contains the PU box but not the octamer sequence, showed the same 
level of EBNA2 responsiveness irrespective of whether the PU box was mutated or not. On 
the other hand, the POU domain protein and its binding site seemed to be instrumental in 
mediating the EBNA2 effect since a -160/-136 LRS fragment conveyed responsiveness to the 
basal TK promoter. These results were in line with EMSA experiments with in vitro translated 
EBNA2, which suggested that EBNA2 interacts with the POU domain protein. The results are 
further strengthened by previous DNasel footprinting experiments indicating that EBNA2 
may modulate the binding of the POU domain protein to the octamer motif [94], 
In conclusion, our findings are consistent with the notion that efficient EBNA2-mediated 
transactivation of the LMP1 promoter requires the cooperation of multiple factors binding to 
different DNA eis elements. We have identified a POU domain protein with the ability to 
target EBNA2 to the promoter. Functional cooperation between the POU domain protein and 
the PU. 1 factor may contribute to the B cell-specific activation of the LMP 1 promoter. 
Paper II 
An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent 
activation of the Epstein-Barr virus LMP1 promoter 
Our studies reported in Paper I reinforced the notion that elements in the promoter proximal 
-106/+40 part of LRS play an essential role in the EBNA2 induced activation of the LMP1 
promoter. Furthermore, a previous investigation from our group suggested that an activating 
transcription factor/cyclic AMP response element (ATF/CRE) in this region of LRS is 
essential for the regulation of the LMP1 promoter and mediates activation of the LMP1 
promoter by cAMP in the absence of EBNA2 [88]. Thus, the objective of our studies reported 
in Paper II was to further define the regulatory elements and transcription factors in the 
proximal part of LRS that contribute to the LMP1 promoter activity in general and EBNA2-
induced activation in particular. In Paper II, we established the importance of the ATF/CRE 
element and an adjacent Sp site by site-directed mutational analysis. We showed that both 
EBNA2-dependent and -independent activation of the promoter occur through the ATF/CRE 
site but are mediated by separate sets of transcription factors. Electrophoretic mobility shift 
assays using specific antibodies revealed that the ATF-1, CREB-1, ATF-2 and c-Jun factors 
bind to the ATF/CRE site as ATF-l/CREB-1 and ATF-2/c-Jun heterodimers whereas the Spl 
and Sp3 factors bind to the Sp site. To determine the ability of these transcription factors with 
regard to transactivation of the LMP1 promoter, transient transfection experiments were 
performed. Expression plasmids for the different factors were transfected into EBV-negative 
DG75 lymphoid cells together with the pgLRS(-106)CAT reporter plasmid and an EBNA2 
expression vector or control plasmid. Mutation of the Sp site largely abolished promoter 
activity both in the presence and absence of EBNA2. The Spl factor activated the unmutated 
reporter plasmid in the absence of EBNA2 but did not increase the activity level induced by 
EBNA2. Overexpression of ATF-1 and CREB-1 in the cells demonstrated that the 
homodimeric as well as the heterodimeric forms of the factors transactivate the LMP1 
promoter in an EBNA2-independent manner and the level of activation was just as high as 
that obtained by EBNA2. The effect was ATF/CRE site dependent. The ATF-2 and c-Jun 
factors, on the other hand, did not activate the LMP1 promoter in the absence of EBNA2, 
neither alone nor together. Coexpression of either ATF-2 or c-Jun with EBNA2 produced 
only a slight increase of promoter activity. However, coexpression of ATF-2 and c-Jun with 
EBNA2 resulted in a strong promoter activation that depended on an intact ATF/CRE site. 
These results were in line with our observation that addition of in vitro translated EBNA2 to a 
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mixture containing in vitro translated ATF-2 and c-Jun abrogated the binding of the 
heterodimeric factor complex to the ATF/CRE site-containing DNA probe in EMSA 
experiments. Notably, EBNA2 did not affect the binding of the respective homodimeric 
complexes of ATF-2 or c-Jun, suggesting that EBNA2 interacted only with the heterodimeric 
factor complex. This notion gained further support by the results obtained by 
immunoprecipitation of complexes in extracts of DG75 cells, which had been co-transfected 
with expression plasmids for ATF-2, c-Jun and EBNA2. Both anti-c-Jun and anti-ATF-2 
antibodies pulled down complexes that contained EBNA2 and the two transcription factors. 
Taken together, these results suggest that the interaction between the c-Jun/ATF-2 complex 
and EBNA2 is an inherent step in the transactivation of the LMP1 promoter. 
Our studies demonstrate that an Sp element at position -33 in LRS is required for efficient 
EBNA2-dependent and EBNA2-independent activation of the LMP1 promoter and that the 
Spl and Sp3 transcription factors bind to this site. Spl is a well-known transcriptional 
activator of different sets of genes of both viral and cellular origin. The limited effect of 
overexpression of the Spl protein on the activity of the promoter in the absence of EBNA2 in 
our transfection experiments may well be explained by high level of Spl in DG75 cells that 
diminishes the relative contribution of the exogenously added protein. Overexpression of Spl 
into the Spl-negative Schneider cells did not induce additional LRS-derived activity (data not 
shown). The Sp3 transcription factor has been shown to function as a repressor of Spl-
mediated transcriptional activation [98]. Multiple Sp3-containing complexes similar to those 
observed in our EMSA analyses have previously been found in another system [99]. We 
suggest that the stimulatory effect of Spl on the LMP1 promoter is independent of EBNA2 
but is a prerequisite for EBNA2-induced activation of LMP1 promoter. The interaction of Spl 
and Sp3 factors with their binding site in LRS might constitute an EBNA2-independent 
regulatory system in which the balance between the positively acting Spl and the negatively 
acting Sp3 factors is one of the factors that determines the final level of activity of the LMP1 
promoter. 
In this paper, we also establish the importance of the ATF/CRE element by mutational 
analysis and show that both EBNA2-dependent and -independent activation of the promoter 
occur via this site but are mediated by separate sets of factors. EMSA with specific antibodies 
showed that the ATF-1, CREB-1, ATF-2 and c-Jun factors bind to the site as ATF-l/CREB-1 
and ATF-2/c-Jun, since the homomeric forms of the factors were not detected. The presence 
of two ATF-l/CREB-1 complexes with different mobilities in the electrophoreto-grams might 
be explained by the previous observation that phosphoiylation drastically changes the 
conformation of ATF-1 and, as a consequence, the electrophoretic mobility of the 
corresponding EMSA complex [100]. It should be noted, however, that overexpression of the 
factors in the cells by transfection with expression vectors under conditions that favored the 
formation of the homodimeric forms showed that these were as efficient in inducing promoter 
activity as was the heterodimeric form. Previous studies have shown that cAMP via protein 
kinase A pathway increases LMP1 expression in the EBV-positive cell lines Cherry and B95-
8 [88], and that treatment of BL cell lines with anti-immunoglobulin or tetradecanoyl phorbol 
acetate (TPA) induces the LMP1 expression independently of EBNA2 via the protein kinase 
C (PKC) signal transduction pathway [90]. It has been shown that the transactivating function 
of CREB-1 and ATF-1 is stimulated by phosphorylation of the factors via the PKA and PKC 
pathways [101, 102], Thus, it is conceivable that EBNA2-independent promoter activation 
through the PKC pathway and the PKA pathway is mediated by the binding of a 
heterodimeric complex between the ATF-1 and CREB-1 factors to the ATF/CRE site. 
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The results of the present study lend strong support to the notion that EBNA2 can activate the 
LMP1 promoter via a mechanism that is different from the ATF-l/CREB-1 pathway and 
involves the binding of the ATF-2 and c-Jun factors as a heterodimer to the ATF/CRE site. 
EBNA2 is required for the activation and, judging from the EMSA and 
coimmunoprecipitation experiments, seems to make a direct contact with the c-Jun/ATF-2 
dimer complex. Thus, the question arises of how this interaction may lead to promoter 
interaction. Does EBNA2 induce a modification of the ATF-2/c-Jun complex and/or its 
binding site or change the concentration of the factors in the cell nucleus in a way that favors 
promoter activation through the activating domains of ATF-2 and c-Jun? Or is EBNA2 
recruited to the LMP1 promoter through protein-protein interactions with the ATF-2/c-Jun 
dimer to bring the EBNA2 transactivating domain in the correct position for a productive 
contact with one or several factors belonging to the basal transcription machinery? The 
possibility also exists that the interaction between EBNA2 and the c-Jun/ATF-2 dimer 
decreases the affinity of this complex for the ATF/CRE site, leading to an increased binding 
of the ATF-1 and CREB-1 factors and activation of the LMP1 promoter through this pathway. 
However, the fact that overexpression of ATF-2 and c-Jun in the presence of EBNA2 has a 
pronounced activating effect argues against such a hypothesis. With regard to the first 
alternative, we have not detected any change in the phosphorylation status or the levels of 
ATF-2 and c-Jun in parallel with the EBNA2-induced activation of the LMP1 promoter. 
Furthermore, it has been demonstrated in several studies that the C-terminal acidic domain of 
EBNA2 is required for transcriptional transactivation by EBNA2 [94, 103, 104]. It has also 
been shown that the activating domain of EBNA2 makes physical contact with several general 
transcription factors, including TFIIB, TFIIE, TFIIH, RPA70, and TAF40 [40-42], Thus, it 
seems possible that EBNA2, at least in the context of the -107/+40 part of LRS, functions in a 
manner analogous to the transcriptional coactivators CBP (CREB-binding protein) and the 
adenovirus ElA-associated cellular protein p300 with regard to ATF/CRE site. Neither CBP 
nor p300 by itself binds to DNA, but they can be recruited to promoter elements by 
interaction with a multitude of sequence-specific activators. CBP can activate transcription 
through the C-terminal part of the protein, and the activation domain has been shown to 
interact with components of the basal transcription machinery [105]. Thus, CBP and p300 are 
transcriptional coactivators that provide a crucial link between transcriptional activators 
stimulated by signaling cascades and initiation of transcription. EBNA2 seems to function 
through a similar mechanism. 
Paper III 
Silencing of the Epstein-Barr virus (EBV) Latent Membrane Protein 1 gene by the 
Max/Madl/mSin3A modulator of chromatin structure 
Paper I and other previous investigations have presented evidence demonstrating that the 
promoter proximal part of LRS contains a negative transcriptional eis element with a major 
role in EBNA2-mediated regulation of LMP1 gene expression in B cells [77-79, 106]. In the 
present study, we have focused on a sequence immediately upstream of the ATF/CRE 
element that contains a potential E-box site involved in silencing of the LMP1 gene. E-box 
sites bind proteins that belong to the basic helix-loop-helix (bHLH) family of transcription 
factors, which regulate the expression of different cellular functions in various differentiated 
cell types. The specific objective of the study was to define the role of the E-box site in the 
EBNA2 responsiveness of the LMP1 promoter and to determine its relation to the previously 
identified negative element in the promoter-proximal LRS region. To analyze the role of the 
E-box containing region in the regulation of LMP1 promoter activity, we generated a series of 
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LRS-CAT reporter plasmids containing 5' deletion mutations of the LRS from position -107 
to -40 and introduced them into the EBV-negative DG75 B-cell line together with an EBNA2 
expression plasmid or an empty control plasmid. The results indicated that the reporter 
plasmids could operationally be divided into three categories according to the pattern of CAT 
expression and the length of the LRS insert. We interpreted the results as follows. The 
properties of the reporter plasmids in category 1 with the shortest LRS fragments are due to 
the effect of the stepwise inclusion of an EBNA2-dependent positive regulatory element. As 
demonstrated in Paper II this element is an ATF/CRE site, and the activating effect is 
mediated by an ATF-2/c-Jun heterodimer. In plasmids belonging to category 2, an EBNA2-
independent positive element and an overlapping negative element have been included in the 
reporter plasmids, with the positive effect dominating in those that contain the shorter LRS 
inserts and the negative effect dominating in the longer LRS inserts. In the third category in 
which the region between -67 and -107 has been added, EBNA2 responsiveness of the 
reporter plasmid was reconstituted to the same level of activation as that obtained with 
pgLRS(-50)CAT. This suggests that the -106/-67 LRS region contains elements that 
participate in the EBNA2-induced alleviation of the repressor effect on the LMP1 promoter. 
Taken together, the results suggest that a repressor element and an EBNA2-independent 
enhancer element overlap with an E-box-homologous motif at position -56 to -51 in the LRS. 
To characterize the pattern of transcription factor binding to the E-box-containing region, we 
performed EMSAs with DG75 nuclear extracts and the relevant oligonucleotide probes. The 
factors binding to the E-box region were identified by antibody supershift analysis using a 
panel of commercially available antibodies against transcription factors. In summary, the 
results demonstrated that the USF, Max, Madl, mSin3A, E12 and E47 tanscription factors 
are present in DG75 cells and interact with the E-box motif-containing sequence in the 
promoter proximal part of the LRS. To assess whether USF transcription factors can activate 
the LMP1 promoter in an EBNA2-independent manner, reporter plasmids containing the 
-106/+40 LRS region were cotransfected with expression vectors for human USF1 and/or 
mouse USF2a into DG75 cells. Transfection of either USF1 or USF2a, resulting in the 
dominant generation of homodimeric forms, transactivated LMP1 promoter-containing 
reporter plasmids in an E-box-dependent manner. Cotransfection of the pgLRS(-106)CAT 
reporter plasmid with expression vectors for USF2a, Max and Madl showed that Max-Madl 
repressed the activity of the LMP1 promoter in an E-box-dependent manner. Cotransfection 
with the mSin3A vector was not necessary because of the abundance of this protein in the 
cells. Thus, the results were compatible with the notion that USF factors activate the LMP1 
promoter in an EBNA2-independent manner via the E-box region and that this activation can 
be downregulated by the Max-Madl-Sin3A factors. 
It is now well established that Max-Mad l-mSin3A functions as a repressor by recruiting 
deacetylases to the promoter, thereby leading to chromatin remodeling and loss of 
transcription factors access to the nucleosome-associated promoter sequences [107], To 
analyze whether the expression of LMP1 from the endogenous EBV genomes was affected by 
an increase of the level of histone acetylation, we performed TSA (trichostatin A, the 
deacetylase inhibitor) induction experiments in three EBV-positive cell lines, Rael, P3HR-1, 
and Daudi. Interestingly, inhibition of deacetylation activity with TSA induced expression of 
the endogenous LMP1 gene in the EBV-transformed cell lines P3HR-1 and Daudi, suggesting 
that the LMP1 promoter can be regulated via Max-Mad l-mSin3 A recruitment of deacetylase 
to the promoter, leading to core histone deacetylation and modulation of chromatin structure. 
However, TSA cannot induce LMP1 expression in highly methylated Rael cells, indicating 
that other regulatory mechanisms also exist to override the TSA effects. The results also 
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revealed the appearance of significant levels of BZLF1 in P3HR-1 and Daudi cells, indicating 
that the lytic cycle was induced in these cells but not in Rael cells. 
In the present study, we show that a silencing element overlaps with a transcriptional enhancer 
element in an LRS sequence that contains an E-box-homologous motif. Mutation of the 
putative repressor-binding site relieved the repression both in a promoter-proximal and a 
complete LRS context, indicating a functional role of the repressor in LMP1 gene regulation. 
This confirms our previous reports that the proximal region of the LMP1 promoter contains a 
negative eis element with a major role in EBNA2-mediated regulation of LMP1 gene 
expression in B-lymphoid cells (Paper I). 
A number of proteins belonging to the bHLH family of transcription factors, including 
transcriptional repressor complex Max-Madl-mSin3A and transcriptional activator USF, as 
well as E12 and E47, bound in a sequence-specific manner to the E-box-containing sequence. 
The Max protein is thought to play an essential role in the function of this biologically 
important group of transcription factors by being a partner in complex formation with Myc or 
Madl to Mad4or with itself (review in [108]). Myc-Max heterodimers, regarded as the 
biologically active form of Myc, transactivate genes involved in cell proliferation and 
apoptosis which contain the specific E-box sequence. Max itself is thought to be 
transcriptionally inert. Myc-Max heterodimers are favored over homodimers when the two 
proteins are at equilibrium, since both the Myc and Max proteins preferentially 
heterodimerize. The Max-Mad dimeric molecules are repressors of Myc-Max-mediated 
transcriptional activation through competition for the same E-box site (review in [108]). 
However, we were unable to demonstrate binding of Myc to the LRS E-box site by supershift 
experiments. Instead, our results demonstrated that USF proteins confer EBNA2-independent 
activity to the LMP1 promoter via the E-box. The USF proteins represent the larger part of the 
LRS E-box binding activity in the B cells investigated in our study. Interestingly, this group 
of transcription factors, while being ubiquitously expressed, is involved in the expression of 
several tissue-specific or developmentally regulated genes [108]. The factors are encoded by 
two distinct genes (the USF1 and USF2 genes) and exist in the form of homomeric and 
heteromeric dimers able to bind to specific Ebox sites. In vivo, four combinations of the 
different USF proteins are prevalent, with the most common species being heterodimers 
between USF1 and USF2a isoforms [109]. Here we show that the E-box is a transcriptional 
enhancer of the LMP1 promoter, which is activated by the USF proteins in an EBNA2-
independent way. We have so far not identified the specific members of the USF factor family 
that interact with the E-box site in LRS. However, the quantitative dominance of the most 
slow-moving USF complex in the EMSA suggests that it corresponds to the USFl-USF2a 
heterodimer. Transfections under conditions that favor the formation of either the homomeric 
or the heteromeric form of USF1 and USF2a suggested that all dimer combinations were 
equally effective in the transactivation of the LMP1 promoter. 
The silencing effect of the E-box motif involved not only competition in binding to the E-box 
motif between Max-Mad l-mSin3 A and USF factors, but also the modulation of chromatin 
structure by recruitment of deacetylases to the promoter. The repressor complex Max-Mad 1-
mSin3A has been shown to function as a repressor by recruiting histone deacetylases 
(HDACs) to the promoter, thereby lowering the level of acetylated histones in the surrounding 
chromatin structure [107]. Acetylation of histone is thought to destabilize nucleosomes and 
facilitate access of regulatory factors to DNA [110]. Inhibition of deacetylation activity by 
trichostatin A induced expression of the endogenous LMP1 gene in EBV-transformed cells 
(P3HR-1 and Daudi), suggesting that the LMP1 promoter can be regulated via Max-Madl-
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mSin3A recruitment of deacetylase to he promoter. This TSA-induced expression of LMP1 
seems to be a direct effect on core histones in the LMP1 promoter region, because of the 
observation that treatment with TSA activated the LMP1 promoter in reporter plasmids 
transfected into DG75 cells (Paper IV). The difference between Rael and the other cell lines 
regarding the sensitivity to TSA might be due to differences in the methylation pattern of the 
LMP1 promoter region, as the LMP1 promoter is only partially methylated in Daudi cells but 
is fully methylated in Rael cells [85, 86], It has also been shown that sequence specific 
methylation is involved in the regulation of the LMP1 promoter [84]. 
Our initial observation of EBNA2-induced transactivation of the LMP1 promoter suggested 
that one important element of the process was the overriding of the effect of a negative 
element in the proximal part of the promoter regulatory sequence. The mechanism for this 
action was, however, not clarified [77, 106], The identification of the Max-Madl-mSin3A 
complex as the likely mediator of the repressor effect and the assumption that repression 
occurs through the recruitment of deacetylases open up a number of possible options for 
EBNA2-induced reversal of repression. In one model, the balance between the binding of the 
Max-Madl-mSin3A complex and USF is influenced by EBNA2 in favor of USF. This could 
be achieved via several conceivable mechanisms. In this way the recruitment of deacetylases 
to the promoter would be impeded. However, comparative DNA binding studies of proteins in 
EBV-negative and EBV-positive cells reveal that factor binding patterns in the E-box region 
are indistinguishable from each other, which would be an argument against this hypothesis. In 
a second model, EBNA2 abolishes the repressive effect of Max-Madl-mSin3A by affecting 
histone acetylation in a more direct manner. Several transcription factors, including Gcn5, 
CBP, p300 and TAFII250, have been shown to possess histone acetyltransferase activity 
[111]. EBNA2 might have a similar catalytic activity or in some indirect way be able to 
recruit histone acetyltransferase activity to the LMP1 promoter. Under the assumption that 
EBNA2 confers acetyltransferase activity, one might also speculate that acetylation of 
nonhistone proteins, such as high-mobility-group proteins or transcription factors, is 
important for transcriptional regulation of the LMP1 promoter and contributes to the 
transactivating function of EBNA2. Another conceivable way for EBNA2 to counteract 
deacetylation and overcome Max-Mad repression would be to recruit the SWI-SNF complex 
to the promoter. The complex remodels chromatin by an ATP-dependent mechanism, creating 
a chromatin structure that is more accessible for protein interactions and thereby for induction 
of transcription. It has, in fact, been shown that EBNA2 can interact with the SWI-SNF 
complex [43]. 
Paper IV 
Cooperation between Epstein-Barr virus Nuclear Antigen 2 (EBNA2) and AP-2 factors 
relieves Max-Madl and Ikaros factor-mediated repression of the LMP1 promoter in B 
cells 
Our previous work showed that repression of the LMP1 promoter is partially mediated by a 
Max-Madl -mSin3A complex bound to an E-box element at position -56 to -51 in LRS (Paper 
III). The data also suggested that a second negative regulatory element was present in the 
adjacent, -67/-59, part of LRS. The repression exerted by the two elements was relieved by 
EBNA2 when elements in the LRS region between -106 and -67 were included. The aim of 
the present study was to investigate the functional significance of the putative transcription 
factor binding sites in the -107 to -52 region of LRS, which in addition to E-box element 
encompasses an Ikaros site at position -67/-59, an NF-KB site at -89/-79, and two AP-2 sites 
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at -80/-72 and -103/-95, respectively. The role of these sites, in EBNA2-induced relief of 
LMP1 repression was investigated using a series of luciferase reporter plasmids carrying LRS 
fragments with 5'-end deletions. The plasmids were transfected into the EBV-negative B-cell 
line DG75 together with the EBNA2 expression plasmid or the empty control vector. Since 
the repression of LMP1 promoter seemed to be due to the recruitment of histone deacetylases 
(HDACs) by the repressive elements, the ability of Trichostatin A (TSA), an inhibitor of 
histone deacetylation, to activate reporter plasmids was also investigated and compared with 
that of EBNA2. The results showed that the Ikaros site added substantially to the inhibition 
exerted by the E-box element on promoter activity. Inclusion of the putative AP-2 and NF-KB 
elements in the LRS plasmid did not increase EBNA2 inducibility (pLRS(-95)LUC). In 
contrast, TSA induced approximately the same level of activity in all of the reporter plasmids, 
showing that TSA unlike EBNA2 could overcome the repression caused by the inclusion of 
the E-box and Ikaros elements in the plasmids lacking the AP-2 element. 
EMSA revealed that Ikaros transcription factors bound to an Ikaros consensus sequence 
adjacent to the previously defined E-box element. The subtype of the Ikaros factors could not 
be defined due to lack of specificity of the antibody that recognized the common C-terminal 
domain present in all Ikaros isoforms. The apparent involvement of the E-box and Ikaros 
elements in LMP1 promoter repression was assessed by mutation analysis. The results 
revealed that the Ebox and Ikaros sites both function as negative eis elements and act in 
concert to repress LMP1 promoter activity. The Ikaros gene family encodes zinc finger DNA-
binding proteins that, based on genetic disruptions in mice, are essential for lineage 
determination and control of proliferation in the lymphoid system (reviewed in [112]). Ikaros 
has many isoforms derived from an alternatively spliced pre-mRNA, and those isoforms work 
in concert with related proteins called Ailos and Helios. They have been reported to function 
both as repressors and activators of transcription depending on the cellular context. In 
lymphocytes, most Ikaros proteins are present in a 2-MDa nucleosome remodeling and 
deacetylation (NuRD) complex that contains 10-12 Ikaros molecules and several other 
proteins including Mi-2ß, an ATP-dependent chromatin remodeler, and HDACs [113]. The 
Ikaros-NuRD complex has potent chromatin remodeling activity in vitro and can deacetylate 
histones. Smaller amounts of Ikaros are found associated with the SWI-SNF remodeling 
complex and with the co-repressors mSin3 and the C-terminal binding protein (CtBP), further 
linking Ikaros function to chromatin remodeling and deacetylation [114, 115]. The results of 
the TSA induction experiments reported in Paper IV and of unpublished chromatin 
immunoprecipitation assays (ChIP) (Palmqvist et al., in manuscript) supported the notion that 
the predominant causative factor in the repression of the LMP1 promoter is hypoacetylation 
of lysine residues in the N-terminal tails of nucleosomal histones. Thus, in the simplest model 
for the formation of the repressed chromatin structure of the LMP1 gene, HDACs are targeted 
to the core promoter via interaction with Max-Mad l-mSin3A bound to the Ebox and with 
Ikaros-NuRD bound to the Ikaros site. The recruited complexes then promote deacetylation of 
nucleosomal histones and the formation of a more condensed chromatin configuration that 
does not permit transcription. However, other mechanisms like DNA methylation are also 
involved in the repression, as inhibition of deacetylation activity by TSA is not sufficient to 
activate LMP1 expression in BL cell line Rael (Paper III) and resting B cells (Palmqvist et al., 
in manuscript). 
The pLRS(-107)Luc plasmid, that contains an AP-2 element at LRS position -103/-95, was 
activated by EBNA2, suggesting that EBNA2-mediated relief of repression depended on the 
presence of an AP-2 site. The AP-2 element was shown to bind the AP-2a, AP-2ß and 
AP-2y factors in EMSA analyses. Mutations that disrupted AP-2 binding to this site abolished 
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EBNA2-induced activation of the promoter in reporter plasmids, supporting the notion that 
the AP-2 site is important in EBNA2-mediated transactivation of the LMP1 promoter. 
Inhibition of HDACs by TSA induced activation of the mutated plasmids. Overexpression of 
AP-2 activated the LMP1 promoter in reporter plasmids in the absence of EBNA2 expression. 
However, a much higher activity was observed in the presence of high levels of both EBNA2 
and AP-2 in the context of the pgLRS(-107)CAT reporter plasmid. Taken together our results 
support the notion that cooperation between EBNA2 and AP-2 might play an important role 
in the activation of LRS. The EBNA2 and the AP-2 factors might act in concert to recruit 
HATs to the promoter and induce acetylation of specific histones, leading to release of 
repression and activation of the LMP1 promoter. It should be noted, however, that the level of 
AP-2a, AP-2ß and AP-2y in the EBV-negative DG75 B cell line is very low as judged from 
western immunoblotting experiments using commercial antibodies against these factors. We 
cannot exclude that some other member of the AP-2 transcription factor family acting via the 
AP-2 element is responsible for the basal cooperative activity with EBNA2 in LMP1 
promoter transactivation. On the other hand it is quite obvious from our overexpression 
experiments that increasing concentrations of AP-2 increases the activity of the LMP1 
promoter at a constant EBNA2 level in a cooperative manner. 
The AP-2 proteins are encoded by a family of related genes, AP-2a [116], AP-2ß [117, 118], 
and AP-2y [118]. The three AP-2 proteins differ in their N-terminal transcription activation 
domains, but show a high degree of conservation (75-85%) within their DNA binding and 
dimerisation domains and bind as homo- or heterodimers to a GC-rich element with the 
consensus sequence GCCNNNGGC [119, 120]. Generally, the transactivating properties of 
the AP-2 proteins are regulated by phosphorylation through the PKA and PKC cellular 
signaling pathways [121, 122]. AP-2 was first characterized as a transactivating protein in 
HeLa cell nuclear extracts [116]. The AP-2 family has since been shown to be involved in 
several other vital cellular functions including cell proliferation, cell death, and programmed 
gene expression both during embryonic morphogenesis and adult cell differentiation 
(reviewed in [123]). The involvement of AP-2 in different cellular functions is attributed to 
its ability to interact with many different cellular and viral proteins, including the 
retinoblastoma tumor suppressor protein, the oncoprotein c-Myc, the transcription factor 
YY1, the simian virus 40 large T antigen, the adenovirus El A protein, and the human T-cell 
leukemia virus type I tax protein, Moreover, AP-2 transcription factors interact with members 
of the CBP/p300-interacting transactivator with ED-rich tail (CITED) family of proteins. 
CITED2 and CITED4 bind CBP and p300 with high affinity and function as coactivators for 
all isoforms of AP-2 [124, 125]. It is well established that CBP/p300 possess intrinsic HAT 
activity [126] and are recruited to gene promoters by diverse DNA-bound transcription factors 
including AP-2. Targeted nucleosomal histone acetylation by such a protein complex 
modifies the chromatin structure rendering promoters more accessible to transcription factors. 
Thus, AP-2 as a DNA-binding factor would have the capacity to recruit HATs to the LMP1 
promoter via CITED and overcome HDAC mediated repression. Different models can be 
proposed for the molecular mechanism underlying the cooperation between EBNA2 and AP-2 
in the transactivation of the LMP1 core promoter. Like AP-2, EBNA2 has been shown to 
interact, directly or indirectly, with CBP/p300 [44]. This, coupled to our observation that the 
transactivating effect of EBNA2 on the LMP1 core promoter is totally dependent of the 
presence of AP-2, suggests that EBNA2 functions as a coactivator of AP-2 in a way 
analogous to that of the CITED factors. Hypothetically, EBNA2 on the one hand interacts 
with AP-2 targeted to the core promoter via the AP-2 binding site and on the other with 
CBP/p300. In this way HAT activity is linked to the core promoter region, locally favoring 
acetylation of nucleosomal histones and chromatin remodeling. A different mechanism for the 
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EBNA2-induced activation of the LMP1 promoter could also be conceived exploiting the 
known ability of EBNA2 to inhibit protein phosphatase 1-like activity [88], thereby increasing 
the level of phosphorylated AP-2 at the promoter. The phosphorylated AP-2 bound to the AP-
2 site might then interact with the CITED4 coactivator and recruit CBP/p300 to the promoter. 
Notably, the two mechanisms would not have to be mutually exclusive. Furthermore, this line 
of argument could also be applied to the reported, EBNA2-independent, activation of the 
LMP1 promoter by TPA and cAMP [88, 89], The transactivating properties of the AP-2 
proteins are known to be regulated by phosphorylation through the PKA and PKC cellular 
signaling pathways [121, 122] which are activated by TPA and c AMP. Consequently, a 
cellular signal that leads to increased phosphorylation of AP-2 may under certain conditions 
also lead to increased expression of LMP1 through the AP-2-CITED4-CBP/p300 pathway. 
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4. Conclusion 
In conclusion, we propose a model for transcriptional regulation of the LMP1 gene in B cells 
(Fig. 5). The LMP1 gene is inactive in the absence of the inducers. The repression 
mechanisms of the LMP1 promoter include histone deacetylation and DNA methylation. Our 
results indicate that HDACs are targeted to the LMP1 promoter via interaction with Max-
Madl-mSin3A bound to the E-box and with Ikaros-NuRD bound to the Ikaros site. The RBP-
JK sites in the distal region of LRS may also be involved in silencing of the LMP1 promoter 
through recruitment of HDACs. 
The expression of LMP1 can be induced by both EBNA2-dependent and -independent 
mechanisms. Our investigations indicate that Spl, ATF-l/CREB-1, USF and AP-2 
transcription factors can transactivate the LMP1 promoter in the absence of EBNA2, through 
Sp, ATF/CRE, Ebox and AP-2 elements at promoter proximal region, respectively. Three 
LRS regions are required for EBNA2-dependent transactivation of the LMP1 promoter, 
including the ATF/CRE element, the octamer motif and PU-box site, and the RBP-JK sites. 
An AP-2 element in the -103/-95 LRS region also participates in the EBNA2-induced relief of 
the repression of the LMP1 promoter. EBNA2 is able to interact with ATF2/c-Jun 
heterodimer, the POU domain protein, PU.l and RBP-JK, to transactivate the LMP1 promoter. 
Several EBNA2 molecules appear to be required in close proximity to enable interactions 
among some or all of the transcription factors that are necessary for appropriate promoter 
regulation. The EBNA2 multimer formed via self-association could enable coordinated 
assembly of multiple factors, including transcription factors, coactivators, histone 
acetyltransferases, and the basal transcriptional machinery, at the LMP1 promoter. By 
bridging among multiple transcriptional regulators, EBNA2 may play a central role in 
regulation of the LMP1 gene (Fig. 5). 
While the results of this study allow a better understanding of the regulation of the LMP1 
promoter activity, their relevance to promoter activation in the in vivo situation, i.e. in the 
context of the physiological promoter, the viral episome and EBV transformation of B cells, is 
not clear. Still, several lines of evidence from this study support a similar scheme for the 
endogenous relief of repression and activation of the LMP1 promoter. The future challenge is 
to study chromatin remodeling and the possible function of EBNA2 as a modulator of the 
nucleosome position at the LMP1 promoter. 
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Figure 5. Hypothetical model for the transcriptional regulation of the LMP1 gene. The EBNA2 is recruited to 
the LMP1 promoter via interacting with the ATF2/c-Jun heterodimer, the POU domain protein, PU.l and RBP-
JK. EBNA2 then recruits multiple complexes (including CBP/P300, SWI/SNF, and the basal transcriptional 
machinery) to remodel the chromatin structure and to activate the LMP1 gene transcription. 
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